HR
NKTR icon

Howe & Rusling’s Nektar Therapeutics NKTR Stock Holding History

Howe & Rusling’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-4
Closed -$1K – 1096
2016
Q2 		$1K Hold
4
– – ﹤0.01% 910
2016
Q1 		$1K Hold
4
– – ﹤0.01% 946
2015
Q4 		$1K Hold
4
– – ﹤0.01% 921
2015
Q3 		$1K Hold
4
– – ﹤0.01% 937
2015
Q2 		$1K Buy
+4
New +$688 ﹤0.01% 968

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Howe & Rusling's NKTR Position: Q3 2016 in Review

Howe & Rusling sold out of Nektar Therapeutics (NKTR) in Q3 2016, closing a stake of 4 shares — an estimated $1K sold.

Howe & Rusling first reported a position in NKTR in Q2 2015 and held it in 5 quarters. The position peaked at $1K in Q2 2016. 194 funds tracked by Wall St. Rank hold NKTR as of Q3 2016.

  • Howe & Rusling reported no remaining Nektar Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Howe & Rusling sold 4 Nektar Therapeutics shares in Q3 2016, an estimated $1K.
  • Howe & Rusling first reported a position in Nektar Therapeutics in Q2 2015 and held it in 5 quarters.
  • Howe & Rusling's Nektar Therapeutics position peaked at $1K in Q2 2016.
  • 194 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2016.

Based on Howe & Rusling's 13F filing for Q3 2016, filed 17 Oct 2016.